Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
about
Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifenSurviving with lung cancer: medication-taking and oral targeted therapy.Tamoxifen and CYP2D6: a contradiction of data.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income womenGenotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.Personalized medicine: is it a pharmacogenetic mirage?Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese populationCYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.The importance of nonpharmacogenetic factors in endocrine therapy.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer.Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians.CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients.Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
P2860
Q27026180-238851E7-F25E-4FC4-97DF-27811D657BC4Q30407705-11876D92-9970-4F37-8CBF-FDD576979226Q34244463-FC1CDFF9-5060-41E3-A0D1-8BBB2A942300Q34307589-283EADAE-184C-4AB6-90A4-7A47F9A890B8Q34355283-CBC242FE-04A8-4467-94E0-CD63FA751E78Q34677193-D8D85972-DBBF-4E47-88C1-5EC5C2B46CBBQ35009604-6D579C4B-55B8-4879-B0DA-5C3D9CC26991Q35056229-E01CB040-5B2E-463B-99A2-C5D2A294B76CQ35058455-94DAEB73-CB07-427E-9E0D-DFFE903BBC52Q35732619-07D9F35A-0030-4CE3-82A5-0CECE8FEA61DQ35909573-D55954D5-861A-4929-9ADD-351EDDB2D92DQ35968741-295F7203-C037-4281-8312-E14E0C82B915Q36218210-3578C249-102B-4EB1-B644-78E35330E3A7Q36336007-D167E797-3B77-4BEE-89F5-7D74DB955127Q36408545-C15BF7B4-63C1-47E4-8FC1-FAC35C49820EQ36713559-7AC50636-7A37-49C5-93B7-A4EA647818FAQ36729040-6CBC9EDC-7B75-43DA-AD24-4F215C3413D6Q37228037-64008EE7-548F-4794-9CDA-1812FF1E8BB4Q37524058-04EC11BC-C8C3-4509-B0C5-799DF0485941Q37533025-F8C3087F-FA31-4486-BF05-CB7DEEE82401Q37876401-F7766093-7787-4E2C-91BE-E016D98928CFQ38003706-F9440E61-B16F-45E1-A622-EF2215E5486AQ38103593-3959D4B3-6FF3-4C12-B67C-D4913353EF41Q38109822-9847CE3D-B81A-45F7-9B7B-3F98AF09E151Q38128209-006F0131-F4B0-453B-882A-8B5B81BC8793Q38364888-B38A7DF2-A503-403E-893F-7AE9FC6455D4Q38404763-E7296F37-B150-4950-ADC1-BF373DD997F1Q38668766-4ECA5606-960D-4E76-9C0C-53D8A524383FQ39042324-9059D706-9176-470F-8421-CEB9884ACEE7Q43987491-20EACD93-0E9A-4A64-8BFD-7D3361C5EDF3Q45901122-0E81C133-2630-471E-B6FA-4A8A8BCE19B1Q48030851-6AEC5548-C0DE-43F1-8CD4-719B1A460A57Q53116333-F3B0ADDA-CE8A-4789-A8DB-84242222CBF6Q53355927-BECCF4E2-F691-44B5-ACD3-9D8C1F3E59C0Q54344347-ED99E3C9-DDC0-4551-A32E-3EE4EA8DD6A6
P2860
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comprehensive CYP2D6 genotype ...... ed with tamoxifen monotherapy.
@en
type
label
Comprehensive CYP2D6 genotype ...... ed with tamoxifen monotherapy.
@en
prefLabel
Comprehensive CYP2D6 genotype ...... ed with tamoxifen monotherapy.
@en
P2093
P50
P1476
Comprehensive CYP2D6 genotype ...... ed with tamoxifen monotherapy.
@en
P2093
Alastair M Thompson
Andrea Johnson
Ayshe Latif
Grantland Hillman
Jeffrey Lawrence
Kirsten D Hadfield
Lee B Jordan
Linda Ashcroft
Marcel Fontecha
Michele Nikoloff
P2888
P304
P356
10.1007/S10549-010-1139-X
P407
P577
2010-09-01T00:00:00Z
P5875
P6179
1010246424